Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology

Characteristic (mean [SD])

Age subgroup

All patients (n = 2220)

≤35 years (n = 692)

>35 years (n = 1528)

Age, years

31.6 (2.57) (n = 692)

38.7 (2.14) (n = 1528)

36.5 (4.00) (n = 2220)

BMI, kg/m 2

23.1 (4.10) (n = 683)

23.1 (3.92) (n = 1502)

23.1 (3.98) (n = 2185)

FSH level (on cycle days 2–4), IU/L

10.6 (12.06) (n = 209)

10.3 (10.91) (n = 395)

10.4 (11.31) (n = 604)

LH level, IU/L

5.22 (7.92) (n = 448)

4.53 (6.57) (n = 837)

4.77 (7.07) (n = 1285)

E 2 level, pg/mL

42.00 (77.51) (n = 431)

43.9 (66.86) (n = 814)

43.3 (70.7) (n = 1245)

AMH, ng/mL

2.1 (3.08) (n = 45)

1.5 (1.56) (n = 135)

1.7 (2.06) (n = 180)

Endometrial thickness, mm

3.42 (3.57) (n = 344)

3.41 (1.66) (n = 717)

3.41 (2.45) (n = 1061)

AFC (number of follicles <11 mm)

6.8 (5.07) (n = 210)

4.5 (3.64) (n = 440)

5.3 (4.29) (n = 650)

  1. AFC = antral follicle count; AMH = anti-Müllerian hormone; BMI = body mass index; E2 = oestradiol; FSH = follicle-stimulating hormone; LH = luteinizing hormone; SD = standard deviation.